Increasing number of
cancer deaths across the globe can be attributed to lung cancer. A
tumor formation by uncontrolled growth of cells in the lung tissues
leads to lung cancer. Non-small cell lung cancers (NSCLC) and Small
cell lung cancers (SCLC) are the two types of lung cancer known so
far. SLCC accounts for 20% share of the lung cancer cases worldwide
while NSLC accounts for around 80% of the cases. The main cause of
lung cancer is inherited genetic predisposition and inhalation of
carcinogenic substance. Tobacco, arsenic, radiations such as X-rays
and UV rays, and asbestos are some of the examples of carcinogens.
Around 87% of lung cancers occur due to tobacco, smoking, passive
smoking, and inhalation of any carcinogenic substance. On the other
hand, genetic predisposition either directly causes cancer or
increases the chances of developing lung cancer due to exposure to
certain environmental factors. Lung cancer can be diagnosed through
biopsy which is carried out using bronchoscopy or CT-guidance. A
combination of surgery, chemotherapy, targeted therapy,
immunotherapy, and radiation therapy are involved in the treatment of
lung cancer. Lung cancer surgery is the surgical ablation of cancer
tissue from the lung. The type of surgery depends upon the size of
the tumor and its position within the lung. This treatment option is
majorly used to treat non-small cell lung cancer. The lung cancer
surgery market is likely to grow due to high success rates as
compared to other therapies available.
The lung cancer
surgery market can be divided into two segments -based on types of
surgery available and products used (surgical & monitoring
devices). Four types of surgery can be performed to treat lung
cancer. These are pneumonectomy, lobectomy, segmentectomy or wedge
resection, and sleeve resection. Pneumonectomy is removal of the
entire lung through surgery and lobectomy is the removal of the
entire cancer affected lobe of the lung. In segmentectomy, a small
wedge shaped piece of lung is excised. In sleeve resection, healthy
parts are reconnected after the removal of the cancerous part of the
bronchus. On the basis of products used, lung cancer surgery can be
classified into minimally invasive surgical procedures (such as
video-assisted thoracoscopic surgery), robot assisted surgery, and
percutaneous transcatheter surgery (radiofrequency ablation,
cryoablation).
Rising occurrence of
lung cancer due to change in lifestyle, increase in the number of
smokers, and rise in the level of air pollution, and technological
advancements in the field of minimally invasive surgeries are some of
the reasons enhancing the growth of the market. According to National
Cancer Institute, the number of deaths due to lung cancer accounted
for around 160,340 in 2012 and there were around 220,160 new lung
cancer diagnosis cases in the same year. World Health Organization
(WHO) claims around 1,824,701 deaths annually due to lung cancer and
that accounts for 13% of total lung cancer cases diagnosed in adults
in 2012. Novel surgical approaches like robotic surgery and other
technological advancements further boosts the growth of the market.
On the other hand, lack of surgical expertise, effective alternative
treatments, limited accessibility to novel approaches, abrupt
location & large size of the tumor, post-surgery pain, and high
cost are some of the restraints faced by the market. High growth
potential in the Asian region provides opportunities for players in
the lung cancer surgery market.
Download Report
Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32156
Geographically, the
market for lung cancer surgery can be distributed into five regions
i.e. North America, Europe, Asia Pacific, Latin America, and Middle
East & Africa. North America dominates the global lung cancer
surgery market. According to World Cancer Research Fund
International, the highest incidence of lung cancer was observed in
Northern America followed by the Asia Pacific region. Rise in the
aging population, increasing incidence of lung cancer, and
reimbursement available for lung cancer surgery are some factors that
drives the growth in the North American market. However, Asia is
expected to expand at the highest growth rate rapidly as expensive
robotic surgeries are being carried out for treatment, which is
anticipated to contribute to the growth of the global lung cancer
surgery market. Factor such as growing population, increase in the
number of newly diagnosed patients, government initiatives for
improvement of healthcare infrastructure, and increasing healthcare
expenditure in Asian countries are driving the market. In Europe,
Hungary had the highest rate of lung cancer, followed by Serbia. In
Latin America and the Middle East & Africa, the incidence of lung
cancer is comparatively lower than most developed countries.
Covidien PLC,
Ethicon US LLC, AngioDynamics Inc., Intuitive Surgical Inc., Accuray
Inc., Teleflex Inc., Scanlan International Inc., Olympus Corporation,
KARL STORZ GmbH, Ackermann Instrumente GmbH, and Trokamed GmbH are
some of the key players of the lung cancer surgery market.
Pre-Book Full
Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=32156<ype=S
About Us
Transparency Market
Research (TMR) is a market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.
Our business offerings represent the latest and the most reliable
information indispensable for businesses to sustain a competitive
edge.
Each TMR syndicated
research report covers a different sector - such as pharmaceuticals,
chemicals, energy, food & beverages, semiconductors, med-devices,
consumer goods and technology. These reports provide in-depth
analysis and deep segmentation to possible micro levels. With wider
scope and stratified research methodology, TMR’s syndicated reports
strive to provide clients to serve their overall research
requirement.
US Office Contact
90 State Street,
Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment